Cosciens Biopharma (CSCI) investor relations material

Executive summary

• Achieved Q2 2026 consolidated net loss of $0.2 million, a significant improvement from $2.7 million net loss in Q2 2025, driven by higher gross margins, increased sales, and reduced expenses.

• First half of 2026 saw consolidated net income of $10.6 million, reversing a $6.4 million net loss in the same period last year, mainly due to $10.9 million income from discontinued operations and operational efficiencies.

• Shareholders approved a share reorganization, enabling suspension of SEC reporting obligations and expected annualized cost savings.

Financial highlights

• Q2 2026 revenue rose to $3.1 million from $2.4 million in Q2 2025; first half 2026 revenue was $5.0 million, up from $3.8 million year-over-year.

• Q2 2026 total operating expenses dropped to $1.3 million from $2.6 million in Q2 2025, with significant reductions in SG&A and R&D costs.

• Cash and cash equivalents stood at $5.3 million as of June 30, 2026.

Outlook and guidance

• Focus remains on supporting subsidiary Ceapro’s growth and exploring opportunities for greater scale as a public company.

• Anticipates significant cost savings from reduced U.S. regulatory compliance following SEC reporting suspension.